Schrezenmeier, Hubert http://orcid.org/0000-0003-1222-6659
Kulasekararaj, Austin http://orcid.org/0000-0003-3180-3570
Mitchell, Lindsay
de Latour, Régis Peffault http://orcid.org/0000-0001-6222-4753
Devos, Timothy http://orcid.org/0000-0002-6881-417X
Okamoto, Shinichiro
Wells, Richard
Popoff, Evan
Cheung, Antoinette http://orcid.org/0000-0003-0335-6611
Wang, Alice
Tomazos, Ioannis http://orcid.org/0000-0003-0290-4583
Patel, Yogesh http://orcid.org/0000-0002-8916-5228
Lee, Jong Wook http://orcid.org/0000-0003-2949-4166
Funding for this research was provided by:
Alexion Pharmaceuticals
Universität Ulm
Article History
Received: 23 March 2023
Accepted: 26 September 2023
First Online: 7 October 2023
Declarations
:
: The protocol for study 301 (NCT02946463) was approved by the institutional review board or independent ethics committee at each participating center, and the study was conducted in accordance with the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines. All patients gave written informed consent.
: Hubert Schrezenmeier has received travel support, fees, and research support (to University of Ulm) from Alexion, AstraZeneca Rare Disease, and Novartis, and fees (to University of Ulm) from Apellis, Roche, and Sanofi. Austin Kulasekararaj has received fees for service, travel support, and consulting fees from Alexion, AstraZeneca Rare Disease. Lindsay Mitchell has received fees from Alexion, AstraZeneca Rare Disease. Prof de Latour received fees for service, travel support, consulting fees and served as a member of an advisory board for Alexion, AstraZeneca Rare Disease, Novartis and Pfizer. Timothy Devos has served as a member of an advisory board for AbbVie, Alexion, AstraZeneca Rare Disease, Celgene/Bristol Myers Squibb, and Novartis. Shinichiro Okamoto has received fees and research funding from Alexion, AstraZeneca Rare Disease. Richard Wells has received fees and research funding from Alexion, AstraZeneca Rare Disease, Celgene, and Novartis, and consulting fees from Alexion, AstraZeneca Rare Disease. Evan Popoff and Antoinette Cheung are full-time employees of Broadstreet HEOR. Yogesh Patel is a full-time employee of Alexion, AstraZeneca Rare Disease. Ioannis Tomazos and Alice Wang were full-time employees of Alexion, AstraZeneca Rare Disease at time of study. Jong Wook Lee has received grants and fees from Alexion, AstraZeneca Rare Disease, and has served as a member of an advisory board for Alexion, AstraZeneca Rare Disease.